Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A section reveal a positive sentiment. Key highlights include the successful launch of PEDMARK in Europe and the U.K., significant expansion plans, and strong growth trends in the AYA patient segment. The field force expansion and the Fennec HEARS program are expected to drive sales growth. While financial guidance is pending, the anticipated revenue from partnerships and the resolution of litigation issues further bolster the outlook. The absence of unclear management responses also supports a positive sentiment.
Key Financial Performance
Net Product Sales (Full Year 2025) $44.6 million, a 50% increase year-over-year from $29.6 million in 2024. This growth was driven by quarter-over-quarter expansion with active patients and new and existing accounts, reflecting the effectiveness of market development strategies.
Net Product Sales (Q4 2025) $13.8 million, a 75% increase year-over-year from $7.9 million in Q4 2024. This growth was attributed to continued momentum in delivering PEDMARK to patients and the leadership team's efforts.
Selling and Marketing Expenses (Q4 2025) $6.1 million, up from $3.9 million in Q4 2024. The increase was due to higher payroll and additional marketing expenses aimed at expanding the commercial team and outreach to oncology centers and the adolescent and young adult population.
Selling and Marketing Expenses (Full Year 2025) $18.6 million, slightly up from $18.4 million in 2024. Increased payroll and marketing expenses were offset by the elimination of European expenses after the Norgine transaction in March 2024.
General and Administrative (G&A) Expenses (Q4 2025) $8.9 million, up from $4.2 million in Q4 2024. The increase was due to higher intellectual property and legal expenses, increased payroll, and noncash stock-based compensation.
General and Administrative (G&A) Expenses (Full Year 2025) $28.8 million, up from $23.1 million in 2024. The increase was driven by higher intellectual property and legal expenses, increased payroll, and noncash stock-based compensation.
Cash and Cash Equivalents (End of 2025) $36.8 million. The increase was primarily due to $42 million in net proceeds from equity offerings and cash collected from net product sales, offset by operating expenses and a $21.5 million debt paydown.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PEDMARK Sales Growth: Record net product sales of $44.6 million in 2025, up from $29.6 million in 2024, driven by quarter-over-quarter expansion in active patients and accounts.
PEDMARK Clinical Evidence: New data presented at the 2026 Multidisciplinary Head and Neck Cancer Symposium supports PEDMARK's use in adults with head and neck cancers, showing feasibility and scalability.
Geographic Expansion: Progress in the Phase II/III STS-J01 clinical trial for PEDMARK in Japan, aiming to expand its global impact and registration in Asia.
Adolescent and Young Adult (AYA) Market: Expanded customer-facing team to target high-prescribing territories and the AYA market.
Financial Health: Raised over $42 million in net proceeds, fully redeemed debt, and achieved the strongest balance sheet in company history.
Operational Efficiency: Fennec HEARS program achieved record performance in patient enrollments, prescribed and infused vials, and conversion rates (70% in Q4 2025).
Litigation Settlement: Settled patent litigation with Cipla, ensuring market exclusivity for PEDMARK in the U.S. until September 1, 2033, saving millions in annual G&A costs.
Marketing Initiatives: Launched initiatives targeting young adult testicular cancer patients, including partnerships with advocacy groups and presence at major events like the Indy 500 and ASCO meeting.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Exclusivity Risk: The settlement of patent litigation with Cipla ensures that Cipla will not enter the market with its generic sodium thiosulfate product until September 1, 2033. However, this indicates a potential risk of generic competition post-2033, which could impact PEDMARK's market share and revenue.
Regulatory and Legal Costs: The company faced increased G&A expenses due to higher intellectual property and legal expenses, including patent litigation. While the litigation was settled, such legal challenges could pose financial and operational risks in the future.
Operational Expansion Challenges: The company has significantly expanded its customer-facing team and commercial outreach, which has increased payroll and marketing expenses. This expansion could strain operational efficiency and financial resources if not managed effectively.
Economic and Cash Flow Management: Although the company anticipates generating positive cash flow in Q1 2026, the timing of receivable collections impacted Q4 cash flows. This highlights a potential risk in cash flow management and dependency on timely receivables.
Clinical Evidence and Adoption Risk: While the company is making progress in generating clinical evidence and engaging with key opinion leaders, broader clinical adoption of PEDMARK is still in progress. Delays or challenges in achieving widespread adoption could impact revenue growth.
Global Expansion Uncertainty: The company is pursuing global expansion, including clinical trials in Japan and potential broader registration in Asia. However, uncertainties in regulatory approvals and market acceptance in these regions pose risks to the success of this strategy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Global Expansion and Sustained Growth: The company plans to focus on execution, global expansion, and sustained growth in 2026 and beyond. This includes advancing the clinical evidence strategy and expanding the applicability of PEDMARK globally, particularly in Japan and potentially broader in Asia.
Clinical Evidence and Medical Initiatives: Fennec aims to generate new data across additional tumor types and patient populations, validate and expand the product's real-world clinical value, and address unmet needs in vulnerable groups such as AYA and adult patients. The company is also focused on strengthening guidelines and practice adoption through independent evidence and deepening collaboration with influential institutions.
New Studies and Collaborations: The company announced the initiation of two new studies with City of Hope and Tampa General Hospital Cancer Institute to evaluate PEDMARK's effectiveness in preventing cisplatin-induced ototoxicity in specific patient groups. Additional investigator-initiated studies are under review.
Market Exclusivity: A settlement with Cipla ensures market exclusivity for PEDMARK in the U.S. until September 1, 2033, which will save millions in annual G&A expenses and support the expansion of the commercial team.
Financial Outlook: The company anticipates generating positive cash flow in the first quarter of 2026, supported by strong receivable collections and a debt-free balance sheet.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the biggest challenge or pushback from physicians or institutions regarding PEDMARK, such as concerns about interference with cisplatin treatment?
A:The primary concern from oncologists has been whether sodium thiosulfate could reduce cisplatin's antitumor activity. Long-term follow-up data from the COG ACCL0431 and SIOPEL 6 trials show no difference in overall survival between PEDMARK plus cisplatin and cisplatin alone, while significantly reducing hearing loss. This evidence reassures that cisplatin's anticancer efficacy is preserved. Additionally, as physicians understand the pharmacology and delayed administration strategy, skepticism is shifting to implementation logistics.
Q:What is Fennec's regulatory strategy for the AYA population, and are they engaging with the FDA or NCCN for guideline placement?
A:Fennec is building a robust evidence generation pipeline, including data from Japan, real-world data on PEDMARK in adults with head and neck cancers, and ongoing ISPs. They are in dialogue with regulatory authorities for label expansion and aim for guideline recognition as evidence grows. The AYA population is a key focus due to the high risk of hearing impairment from cisplatin-based regimens. Fennec plans to pursue regulatory and guideline pathways as data matures.
Q:Can you provide an estimate of cash operating expenses for 2026 versus 2025, considering commercial expansion and awareness initiatives?
A:Cash operating expenses are expected to grow from approximately $35 million in 2025 to $50 million in 2026. The increase is driven by expanded commercial and medical efforts, including increased headcount, awareness initiatives, additional ISPs, and advocacy initiatives. Fennec anticipates a clean P&L in 2026, with gross-to-net drop-down of 85%, COGS in the mid-single digits, and noncash stock compensation in line with 2025. Spending is focused on growing PEDMARK utilization and net product sales, with over 60% of expenses in the first half of 2026.
Q:Can you provide an update on the Norgine partnership and ex-U.S. progress?
A:PEDMARQSI (PEDMARK in Europe) was launched in the U.K. and Germany in 2025 and recently approved in Switzerland. Norgine plans 8-10 launches in 2026, including major EU countries. The U.K. price was set at approximately GBP 8,000 in 2025, with German pricing updates expected mid-2026. Significant momentum is expected in the second half of 2026 as additional countries launch and commercial activities expand.
Q:When will Fennec provide revenue or EBITDA guidance in 2026?
A:Fennec plans to evaluate issuing revenue and EBITDA guidance as growth initiatives impact financials. Every additional 100 patients on PEDMARK could add $30 million in net revenue and $0.70 per share in free cash flow. The AYA market alone has an addressable market of over 20,000 patients annually, and Fennec aims to ramp up commercial team presence in the first half of 2026.
Q:Can you elaborate on the recent field force expansion and its impact on sales?
A:The field force expansion in Q1 2026 aims to increase reach and frequency of territory managers, focusing on high Tier 1 accounts and high-potential new centers. This targeted approach is expected to drive growth and ramp up sales throughout 2026.
Q:How is the Fennec HEARS program impacting commercial demand and revenues?
A:The Fennec HEARS program addresses access barriers, ensuring patients start and complete therapy. It simplifies reimbursement and affordability challenges, leading to record enrollments and growing familiarity among providers. The program supports sustained growth by converting prescriptions into treated patients and improving the patient and clinician experience.
Q:What is the current status of PEDMARK adoption in the germ cell tumor and testicular cancer group?
A:Germ cell tumors represent the largest opportunity for PEDMARK. Fennec is partnering with advocacy groups to educate physicians and patients. Both academic and community settings show substantial interest, driven by the medical team's expertise and detailed discussions on cisplatin's mechanisms and PEDMARK's protective effects.
Q:What are the growth trends in the AYA patient segment, and are there increases in high-frequency prescribers?
A:The AYA patient segment is experiencing significant growth, with a focus on expanding in both academic and community settings. Existing accounts are showing increased vial usage, and there is a balanced mix of new and repeat prescribers. The organization expects continued growth in this segment.
Q:When will revenue contributions from the Norgine partnership and Japan market be realized?
A:Material contributions from the Norgine partnership are expected in the second half of 2026 as launches expand. In Japan, Fennec is in discussions with potential partners to initiate the regulatory process, aiming for approval and market entry as soon as possible.
Q:What is the status of generic filers following the Cipla settlement?
A:The Cipla settlement resolved Fennec's only outstanding litigation. No other litigations are pending, and the company is focused on establishing PEDMARK as the standard of care well into the 2030s.
Q:What are the current trends in unique AYA accounts or prescribers, and how is repeat prescribing evolving?
A:Fennec is seeing strong growth in repeat prescribing as physicians become more comfortable with PEDMARK and the Fennec HEARS program. The commercial team expansion is increasing reach and driving growth in both new and existing accounts, with a balanced approach to customer engagement.
Q:What are the growth expectations for Q1 2026, and is there any seasonality to consider?
A:Fennec expects continued growth momentum in Q1 2026, with significant contributions from the expanded commercial team anticipated in the second half of the year. There is no indication of seasonality impacting the business.
Q:What is Fennec's business development strategy, and how will institutional-led research impact the company?
A:Fennec is focused on maximizing the PEDMARK opportunity while evaluating potential late-stage or commercial assets. Institutional-led research, such as partnerships with City of Hope, is expected to drive new data, regulatory strategies, and expanded label opportunities, strengthening Fennec's position in the market.
Q:Review of Unclear Management Responses
A:No questions were identified where management avoided giving a direct answer or lacked clarity in their responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AYA adult
Cancer
City Hope
Dr
II III
KOL
Pharmaceuticals Full
QA session
School
TGH
access support
adult head
affair
antitumor activity
applicability
cell tumor
center City
chapter
cisplatin antitumor
clinician
collaboration
confidence adoption
conversion rate
customer
development strategy
evidence generation
finding
foundation
hearing
oncology center
opinion leader
priority
program
review
study
use
world
FENC Transcript
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance, with a 73% increase in net product sales and positive cash flow. The strategic global expansion and clinical initiatives, coupled with market exclusivity until 2033, further strengthen the outlook. Despite minor concerns about milestone payment uncertainties and operational ramp-up, the positive sentiment is bolstered by optimistic guidance, robust shareholder return plans, and the potential for label expansion through ISTs. The Q&A session supports this sentiment, highlighting growth in demand and strategic targeting of high-volume prescribers.
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Positive3-24
The earnings call summary and Q&A section reveal a positive sentiment. Key highlights include the successful launch of PEDMARK in Europe and the U.K., significant expansion plans, and strong growth trends in the AYA patient segment. The field force expansion and the Fennec HEARS program are expected to drive sales growth. While financial guidance is pending, the anticipated revenue from partnerships and the resolution of litigation issues further bolster the outlook. The absence of unclear management responses also supports a positive sentiment.
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call highlights strong financial performance with an 18% sales growth, expansion into new markets, and optimistic future revenue expectations. The Q&A session reveals positive growth in new and repeat customers and strategic market expansion, particularly in the AYA segment, despite some reluctance to share specific numbers. The company's strategy to enhance programs and expand in Europe and Japan indicates a proactive approach, supporting a positive sentiment. However, the lack of specific guidance and royalty impact tempers the outlook slightly, leading to a positive rather than strong positive rating.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents mixed signals. Financial performance shows growth, but cash burn and competitive pressures are concerns. The international launch and market expansion are positive, but regulatory and supply chain risks loom. The Q&A reveals some management opacity, particularly around breakeven figures. Without a share repurchase plan and given the lack of strong guidance, the sentiment leans neutral. The absence of market cap data limits the assessment of stock price sensitivity.
FENC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
